Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The term “Myometrial smooth muscle cell ion channel” does not specify a single molecular target, but instead refers to the ensemble of ion channels responsible for establishing and regulating the membrane potential and excitability in myometrial (uterine smooth muscle) cells. These include several families of ion channels such as L-type and T-type calcium channels (CACNA1C and related genes), voltage-gated, ATP-sensitive, and Ca^2+-activated potassium channels (Kv, Kir, KCNMA1/BK, Slo2/Slick, KCNN1-4), voltage-gated and leak sodium channels (SCN, NALCN), and calcium-activated chloride channels (TMEM16A/ANO1). These channels coordinate the transition of the uterus from a quiescent state during pregnancy to a contractile state during labor by controlling action potential generation, propagation, and the resulting muscle contraction or relaxation. Alteration in any of these channels can affect uterine contractility and are implicated in disorders like preterm labor. Drugs targeting individual channel types, such as L-type calcium channel blockers (nifedipine) or K^+^ channel modulators, are used clinically to manage uterine contractility. However, this designation is not the canonical full name of a single target, but a broad descriptive term that should be replaced with the specific channel's name (e.g., “Calcium-activated chloride channel TMEM16A (ANO1)” or “L-type calcium channel”). Therefore, it is not a single, specific molecular target, and use of this phrase as a canonical target name is inaccurate. If the intention is to refer to a specific channel (e.g., TMEM16A/ANO1 for Ca^2+-activated Cl^-^ currents, or CACNA1C for L-type Ca^2+), use the precise molecular target name. If general discussion of uterine excitability is intended, reference the “ion channel repertoire of myometrial smooth muscle”.
Blockade or modulation of calcium, potassium, or chloride channels to alter excitability and contraction
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Myometrial smooth muscle cell ion channel.